[
  {
    "ts": null,
    "headline": "Boston Scientific (BSX): Examining Valuation Following Leadership Change and FARAPULSE FDA Rollout",
    "summary": "A major leadership change can quickly shift the conversation around a stock, and that is exactly what we have with Boston Scientific (BSX) this week. With news that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire later this year, investors are left weighing what this transition means for one of the company's most important divisions. The timing is especially significant because this announcement comes just as Boston Scientific is in the...",
    "url": "https://finnhub.io/api/news?id=ae19e82f899757a8589dd913422b2261cffa067ac8217fcb827f5b64ead25a63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757595758,
      "headline": "Boston Scientific (BSX): Examining Valuation Following Leadership Change and FARAPULSE FDA Rollout",
      "id": 136704073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "A major leadership change can quickly shift the conversation around a stock, and that is exactly what we have with Boston Scientific (BSX) this week. With news that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire later this year, investors are left weighing what this transition means for one of the company's most important divisions. The timing is especially significant because this announcement comes just as Boston Scientific is in the...",
      "url": "https://finnhub.io/api/news?id=ae19e82f899757a8589dd913422b2261cffa067ac8217fcb827f5b64ead25a63"
    }
  },
  {
    "ts": null,
    "headline": "Elutia to divest bioenvelopes business to Boston Scientific for $88m",
    "summary": "This transaction will allow Elutia to advance its development and commercialisation efforts of its near-term pipeline without diluting shareholder value.",
    "url": "https://finnhub.io/api/news?id=a226ebb57ebf4b2a607ec643b12143120bcfdfd1bc4478e45bd4fcb04cbac59b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757585916,
      "headline": "Elutia to divest bioenvelopes business to Boston Scientific for $88m",
      "id": 136704074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "This transaction will allow Elutia to advance its development and commercialisation efforts of its near-term pipeline without diluting shareholder value.",
      "url": "https://finnhub.io/api/news?id=a226ebb57ebf4b2a607ec643b12143120bcfdfd1bc4478e45bd4fcb04cbac59b"
    }
  }
]